Status:

COMPLETED

Bone Marrow Derived Adult Stem Cells for Chronic Heart Failure

Lead Sponsor:

Barts & The London NHS Trust

Conditions:

Chronic Ischaemic Heart Failure

Eligibility:

All Genders

18+ years

Phase:

PHASE2

PHASE3

Brief Summary

The purpose of this study is to determine whether adult bone marrow derived stem/progenitor cells improve cardiac function and symptoms in patients with heart failure and to establish the optimal meth...

Detailed Description

The study involves three arms that compare the method of autologous bone marrow cel administration in patients with chronic heart failure. Each arm has a comparative group that contains either saline ...

Eligibility Criteria

Inclusion

  • Symptomatic patients with a diagnosis of heart failure secondary to ischaemic heart disease who are on optimal heart failure treatment and no further treatment options available
  • Patient has been considered for an implantable defibrillator in keeping with NICE guidelines

Exclusion

  • Recent acute coronary syndrome as judged by a rise of Troponin above normal values in the last 6 months
  • The presence of cardiogenic shock
  • The presence of acute left and/or right-sided pump failure as judged by the presence of pulmonary oedema and/or new peripheral oedema
  • Known severe pre-existent left ventricular dysfunction (ejection fraction \< 10% prior to randomisation)
  • Congenital cardiac disease
  • Cardiomyopathy secondary to a reversible cause e.g. thyroid disease, alcohol abuse, hypophosphataemia, hypocalcaemia, cocaine abuse, selenium toxicity \& chronic uncontrolled tachycardia
  • Cardiomyopathy in association with a neuromuscular disorder e.g. Duchenne's progressive muscular dystrophy
  • Contra-indication for bone marrow aspiration
  • Known active infection
  • Known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) syphilis or HTLV
  • Lifestyle with high risk for infection with HIV, HBV or HCV syphilis or HTLV
  • Serum creatinine \>200 umol/L
  • Chronic inflammatory disease
  • Serious known concomitant disease with a life expectancy of less than one year
  • Follow-up impossible (no fixed abode, etc)
  • Previous participation in this study
  • Female subjects of childbearing potential
  • Atrial fibrillation
  • Patients who have responded to the implantation of a biventricular pacemaker
  • Weight \>140kg

Key Trial Info

Start Date :

August 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2013

Estimated Enrollment :

148 Patients enrolled

Trial Details

Trial ID

NCT00747708

Start Date

August 1 2005

End Date

May 1 2013

Last Update

October 9 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

London Chest Hospital, Barts and the London NHS Trust

London, London, United Kingdom, E2 9JX